Episode Details

MedTech and Pharma companies are using AI to speed up regulatory submissions, but many are finding that faster output is actually leading to more rejections. This episode unpacks a 2026 white paper from IQVIA detailing why speed-first AI fails by treating regulations like a checklist, missing crucial cross-functional inconsistencies. Listeners will learn why shifting from pure speed to patient-centric velocity—and embedding AI directly into regulatory workflows—is the only way to build defensible submissions that regulators can trust.

Key points

• AI optimized solely for throughput validates completeness rather than correctness, accelerating mistakes and hallucinations.
• Speed-first AI systems miss cross-functional inconsistencies between clinical evidence, technical data, quality, and labeling claims.
• Global regulators now have access to their own AI tools, allowing them to spot disjointed, speed-driven submissions instantly.
• IQVIA argues for a shift to velocity—speed combined with intentional, patient-centric direction grounded in clinical evidence.
• AI should be embedded directly into Regulatory Information Management workflows rather than layered on top, catching potential objections before submission.
• Accountability remains with human regulatory professionals, who must ensure the submission tells a clear, defensible story about patient safety.

Source: Speed Can Mislead: Why Velocity Matters Most in Global Regulatory Affairs - IQVIA, 2026

This spot is available. Reach clinicians, health-system leaders and medtech and pharma teams following AI in medicine. Sponsor the show

This episode is an AI-generated conversation summarising a public document; the hosts' voices are synthetic. It is for information only and is not medical advice. Always refer to the original source.

Full transcript: https://ai-in-medicine-podcast.vercel.app/episodes/why-faster-ai-submissions-mean-slower-approvals-iqvia-on-regulatory-ve-0bafdc